Market CapSEK1833.8m

Last Close SEK35

BONESUPPORT is an orthobiologics company that has commercialised three synthetic bone graft substitutes and has several other projects in R&D. The marketed products, CERAMENT BVF, CERAMENT G (gentamicin) and CERAMENT V (vancomycin), are intended to help orthopaedic surgeons manage bone voids and defects after injuries or diseases affecting bones.

More Bonesupport content >

Investment summary

BONESUPPORT’s investment case rests on three strategic pillars: effective commercial organisation, products backed by clinical data and R&D innovation. The company is selling CERAMENT bone void filler (BVF) in the US and Europe, and two antibiotic-eluting BVF products, CERAMENT G/V in Europe. The company has set up a network of its own independent distributors to promote CERAMENT BVF in the US. It has signed agreements with MTF Biologics and Collagen Matrix to grow its product offering sold through its US platform, and has launched a DBM product BONIFY. We are updating our estimates.

Y/E Dec
Revenue (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2018A 96.6 (172.8) (174.1) (344.64) N/A N/A
2019A 155.5 (156.3) (157.5) (308.89) N/A N/A
2020E N/A N/A N/A N/A N/A N/A
2021E N/A N/A N/A N/A N/A N/A
Industry outlook

Innovation is one of the key strategic directions for BONESUPPORT to differentiate its products from competitors offering commodity-like bone graft substitutes. The company has gathered data and is undertaking clinical trials to support the claims of its marketed products.

Last updated on 27/04/2020
Content on Bonesupport
BONESUPPORT – On track to reach profitability
Healthcare | Update | 1 August 2019
Bone grafts
Healthcare | Edison Explains | 23 April 2019
View more
Share price graph
Balance sheet
Forecast net cash (SEKm) 87.6
Forecast gearing ratio (%) N/A
Price performance
Actual 40.0 (7.7) 53.5
Relative* 26.4 7.5 63.5
52-week high/low SEK40.1/SEK20.8
*% relative to local index
Key management
Emil Billbäck CEO
Håkan Johansson CFO